Compare Novo Nordisk A/S (NVO) vs Spotify Technology (SPOT) Price & Performance

Novo Nordisk A/STrade

Spotify TechnologyTrade

Price performance (Past 24H)

Key statistics

Novo Nordisk A/S vs Spotify Technology — how do they compare? Novo Nordisk A/S trades at $46.2 (market cap $207.85B), while Spotify Technology trades at $490.71 (market cap $103.00B). The key difference: Novo Nordisk A/S is far larger — about 2× Spotify Technology's market cap, and Novo Nordisk A/S pays a 3.81% dividend while Spotify Technology pays none. Which is the better fit depends on your goals.

	NVO	SPOT
Market Cap	$207.85B	$103.00B
Sector	Health	Media
52-Week High	$63.98	$738.53
52-Week Low	$35.29	$412.75
Enterprise Value	$222.55B	$92.70B
Dividend Yield	3.81%	—

View details →View details →

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Novo Nordisk A/S

NVO trades at $47.73, up 0.99% today, with a neutral technical signal and strong fundamentals, including a P/E of 11.62 and net income margin of 35.35%. Recent Q2 2026 earnings beat expectations, but the stock faces mixed sentiment due to competitive pressures and pricing headwinds in its GLP-1 portfolio.

The outlook is cautiously optimistic, supported by robust profitability and analyst buy ratings (57.9%), but risks include intense competition from Eli Lilly and margin compression. Upside potential hinges on execution against guidance, while downside risks stem from market share erosion.

Spotify Technology

Spotify (SPOT) trades at $511.82, up 4.85% with a bullish technical outlook. The company reported strong Q2 2026 results with revenue growth and record gross margins, though earnings missed estimates due to higher AI and marketing costs. Analyst consensus is bullish with a $598.20 price target, supported by 61.5% buy ratings. Recent news highlights Spotify's initiative to label AI-generated artists, enhancing platform transparency.

The outlook remains positive with robust subscriber growth and monetization efforts, but risks include competitive pressures and cost management. Upside potential exists if execution continues, while misses on user growth or margin targets could weigh on the stock. The current valuation reflects optimism for sustained profitability.

Aura AI is an analytical signal, not financial advice — do your own research.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

NVO

Novo Nordisk stays a Buy with strong obesity drug lead and improved 2026 outlook despite near-term challenges.Seeking Alpha · 5 hours agoBullish Novo Nordisk faces sell rating amid rising competition and operational challenges, with price target cut to $47.Alex Lavoie · 6 hours agoBearish View details →

SPOT

Spotify to label AI-generated music accounts and exclude them from recommendationsNew York Post · 1 day agoNeutral Spotify labels AI-generated artists with 'AI Persona' tags, excluding them from recommendations.TechCrunch · 1 day agoNeutral View details →

About Novo Nordisk A/S

With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.

About Spotify Technology

Spotify Technology S.A. provides music streaming services. The Company offers commercial-free music and ad-supported services to subscribers. Spotify Technology serves clients worldwide.